$GLMD Headlines
Post# of 144482
Why Galmed Pharmaceuticals (GLMD) Stock Is Surging Today
3:50 p.m. Sept. 23, 2014
- TheStreet.com
Aramchol Fast Track'd
11:24 a.m. Sept. 23, 2014
- Seeking Alpha
Biotech Stocks With Upside Target Ebola, Liver Disease
6:30 a.m. Sept. 16, 2014
- InvestorPlace.com
Biotechs With Upside Target Ebola And Liver Disease: MLV's Vernon Bernardino
9:16 a.m. Sept. 11, 2014
- Seeking Alpha
Venture Capitalist Ran Nussbaum Brings Big Finance To Little Biotechs
8:31 a.m. April 4, 2014
- Seeking Alpha
IPO Preview: Galmed Pharmaceuticals
12:25 a.m. March 13, 2014
- Seeking Alpha
Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH
10:47 a.m. Sept. 23, 2014
- PR Newswire - PRF
Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events
8:00 a.m. Sept. 2, 2014
- PR Newswire - PRF
Galmed Pharmaceuticals Reports First Half 2014 Financial Results
8:00 a.m. July 25, 2014
- PR Newswire - PRF
Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
9:20 a.m. July 22, 2014
- PR Newswire - PRF
Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014
9:08 a.m. July 21, 2014
- PR Newswire - PRF
Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal
10:33 a.m. July 8, 2014
- PR Newswire - PRF
Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs
9:42 a.m. June 26, 2014
- ACCESSWIRE
Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy
8:01 a.m. June 9, 2014
- GlobeNewswire
Recently Published Independent Research Supports the Importance of Reverse Cholesterol Transport on NASH Pathogenesis
8:01 a.m. June 4, 2014
- GlobeNewswire
Galmed Pharmaceuticals Reports First Quarter 2014 Financial Results
4:51 p.m. May 15, 2014
- PR Newswire - PRF
Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies
5:57 p.m. April 28, 2014
- PR Newswire - PRF
Leading Companies Being Defined in the Hunt for a NASH Treatment
10:33 a.m. March 27, 2014
- ACCESSWIRE
Galmed Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
11:40 a.m. March 18, 2014
- PR Newswire - PRF
Galmed Pharmaceuticals Announces Pricing of Initial Public Offering
8:07 p.m. March 12, 2014
- PR Newswire - PRF